Results 271 to 280 of about 644,115 (313)
Some of the next articles are maybe not open access.
Mayo Clinic proceedings, 2019
OBJECTIVE To explore the efficacy and safety of direct oral factor Xa inhibitors in the treatment of cancer-associated acute venous thromboembolism (VTE).
H. Fuentes +6 more
semanticscholar +1 more source
OBJECTIVE To explore the efficacy and safety of direct oral factor Xa inhibitors in the treatment of cancer-associated acute venous thromboembolism (VTE).
H. Fuentes +6 more
semanticscholar +1 more source
2006
The importance of factor Xa in the initiation and propagation of coagulation, as well as its pluripotential cellular properties, has been discussed previously. Considered collectively, the effects exhibited by this particular protease make it an attractive target for pharmacologic inhibition. Factor Xa inhibition can be classified and subcategorized as
Richard C. Becker, Frederick A. Spencer
openaire +1 more source
The importance of factor Xa in the initiation and propagation of coagulation, as well as its pluripotential cellular properties, has been discussed previously. Considered collectively, the effects exhibited by this particular protease make it an attractive target for pharmacologic inhibition. Factor Xa inhibition can be classified and subcategorized as
Richard C. Becker, Frederick A. Spencer
openaire +1 more source
Isoxazolines and isoxazoles as factor Xa inhibitors
Bioorganic & Medicinal Chemistry Letters, 2000AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.
Ruth R. Wexler +7 more
openaire +4 more sources
Synthetic inhibitors of coagulation factor Xa
Expert Opinion on Investigational Drugs, 1999The antithrombotic efficacy of low molecular weight heparins suggest that specific inhibition of blood coagulation factor Xa (fXa) is an appropriate target for drug discovery. Clinical evidence also supports the effectiveness of warfarin, an orally bioavailable non-specific anticoagulant.
openaire +3 more sources
Betrixaban – the next direct factor Xa inhibitor?
Expert Review of Hematology, 2016Venous thromboembolism is a major global health burden. Since the 1930s, prevention of stroke and pulmonary embolism in these patients has been achieved using conventional anticoagulants, such as heparin and warfarin. However, in recent years, four direct non-vitamin K antagonist oral anticoagulants (DOACs) have entered the market as alternative ...
Thoenes, Martin +4 more
openaire +4 more sources
Factor Xa Inhibitors in the Control of Thrombogenesis [PDF]
Hämostaseologie, 1999 SummaryIt is now well recognized that drugs with sole anti-Xa activity are capable of producing antithrombotic effects. The basic and clinical studies with pentasaccharide have validated this hypothesis. Synthetic heparin pentasaccharide is currently undergoing clinical trials in the prophylaxis of DVT in orthopedic surgery.
Walter Jeske +4 more
openaire +1 more source
The Laryngoscope, 2018
To describe the characteristics and severity of epistaxis in patients taking factor Xa inhibitors novel anticoagulants.
E. Glikson +7 more
semanticscholar +1 more source
To describe the characteristics and severity of epistaxis in patients taking factor Xa inhibitors novel anticoagulants.
E. Glikson +7 more
semanticscholar +1 more source
2023
This chapter describes factor Xa as a key enzyme involved in thrombosis and clot formation. It considers factor Xa inhibitors as potential anticoagulants for the treatment of deep-vein thrombosis and pulmonary embolism. It also highlights the first factor Xa inhibitors to reach the market and covers the design process that led to the discovery of ...
openaire +1 more source
This chapter describes factor Xa as a key enzyme involved in thrombosis and clot formation. It considers factor Xa inhibitors as potential anticoagulants for the treatment of deep-vein thrombosis and pulmonary embolism. It also highlights the first factor Xa inhibitors to reach the market and covers the design process that led to the discovery of ...
openaire +1 more source
Progress in the discovery of Factor Xa inhibitors
Expert Opinion on Therapeutic Patents, 2006Factor Xa is a serine protease that has a critical role in the blood coagulation cascade by ultimately regulating the production of thrombin. There is now ample evidence for the role of Factor Xa inhibitors as anticoagulants and they represent potential new therapeutic agents for the treatment and prevention of arterial and venous thrombosis.
Danette Dudley +5 more
openaire +2 more sources
Edoxaban, a Novel Oral Factor Xa Inhibitor
Annals of Pharmacotherapy, 2015Objective: To evaluate the current literature and potential clinical role of edoxaban (Savaysa) for stroke prevention in nonvalvular atrial fibrillation (NVAF) and treatment of deep-vein thrombosis and pulmonary embolism. Data Sources: A PubMed and Cochrane Central Register of Controlled trials search was conducted in February2015 using the search ...
Katie B. Tellor +2 more
openaire +3 more sources